129 related articles for article (PubMed ID: 38340443)
41. Significant association of PKM2 and NQO1 proteins with poor prognosis in breast cancer.
Zhu K; Li Y; Deng C; Wang Y; Piao J; Lin Z; Chen L
Pathol Res Pract; 2020 Nov; 216(11):153173. PubMed ID: 32841776
[TBL] [Abstract][Full Text] [Related]
42. Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides.
Kucera HR; Livingstone M; Moscoso CG; Gaikwad NW
Free Radic Res; 2013 Dec; 47(12):1016-26. PubMed ID: 24074361
[TBL] [Abstract][Full Text] [Related]
43. Interactions of the antioxidant enzymes NAD(P)H: Quinone oxidoreductase 1 (NQO1) and NRH: Quinone oxidoreductase 2 (NQO2) with pharmacological agents, endogenous biochemicals and environmental contaminants.
Rashid MH; Babu D; Siraki AG
Chem Biol Interact; 2021 Aug; 345():109574. PubMed ID: 34228969
[TBL] [Abstract][Full Text] [Related]
44. Near-Infrared Fluorescence Probe with a New Recognition Moiety for Specific Detection and Imaging of Aldehyde Dehydrogenase Expecting the Identification and Isolation of Cancer Stem Cells.
Wang Q; Li Z; Hao Y; Zhang Y; Zhang C
Anal Chem; 2022 Dec; 94(49):17328-17333. PubMed ID: 36453832
[TBL] [Abstract][Full Text] [Related]
45. Collapse of the native structure caused by a single amino acid exchange in human NAD(P)H:quinone oxidoreductase(1.).
Lienhart WD; Gudipati V; Uhl MK; Binter A; Pulido SA; Saf R; Zangger K; Gruber K; Macheroux P
FEBS J; 2014 Oct; 281(20):4691-4704. PubMed ID: 25143260
[TBL] [Abstract][Full Text] [Related]
46. In vivo imaging of alkaline phosphatase in tumor-bearing mouse model by a promising near-infrared fluorescent probe.
Liu HW; Hu XX; Zhu L; Li K; Rong Q; Yuan L; Zhang XB; Tan W
Talanta; 2017 Dec; 175():421-426. PubMed ID: 28842011
[TBL] [Abstract][Full Text] [Related]
47. Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.
den Braver-Sewradj SP; den Braver MW; Toorneman RM; van Leeuwen S; Zhang Y; Dekker SJ; Vermeulen NPE; Commandeur JNM; Vos JC
Chem Res Toxicol; 2018 Feb; 31(2):116-126. PubMed ID: 29281794
[TBL] [Abstract][Full Text] [Related]
48. A highly selective and easily acquisitive near-infrared fluorescent probe for detection and imaging of hydrogen sulfide in cells.
Wang Z; Li Y; Zhang Q; Jing C; Jiang Y; Yang T; Han T; Xiong F
Spectrochim Acta A Mol Biomol Spectrosc; 2023 May; 293():122428. PubMed ID: 36773422
[TBL] [Abstract][Full Text] [Related]
49. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
[TBL] [Abstract][Full Text] [Related]
50. Role of NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity.
Joseph P; Long DJ; Klein-Szanto AJ; Jaiswal AK
Biochem Pharmacol; 2000 Jul; 60(2):207-14. PubMed ID: 10825465
[TBL] [Abstract][Full Text] [Related]
51. Cancer-Specific hNQO1-Responsive Biocompatible Naphthalimides Providing a Rapid Fluorescent Turn-On with an Enhanced Enzyme Affinity.
Park SY; Jung E; Kim JS; Chi SG; Lee MH
Sensors (Basel); 2019 Dec; 20(1):. PubMed ID: 31861836
[TBL] [Abstract][Full Text] [Related]
52. Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system.
Volpato M; Abou-Zeid N; Tanner RW; Glassbrook LT; Taylor J; Stratford I; Loadman PM; Jaffar M; Phillips RM
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3122-30. PubMed ID: 18089707
[TBL] [Abstract][Full Text] [Related]
53. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
Colucci MA; Moody CJ; Couch GD
Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
[TBL] [Abstract][Full Text] [Related]
54. NAD(P)H:quinone oxidoreductase 1 reduces the mutagenicity of DNA caused by NADPH:P450 reductase-activated metabolites of benzo(a)pyrene quinones.
Joseph P; Jaiswal AK
Br J Cancer; 1998 Mar; 77(5):709-19. PubMed ID: 9514048
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development.
Beall HD; Winski SI
Front Biosci; 2000 Jul; 5():D639-48. PubMed ID: 10877993
[TBL] [Abstract][Full Text] [Related]
56. Quinone-Modified Mn-Doped ZnS Quantum Dots for Room-Temperature Phosphorescence Sensing of Human Cancer Cells That Overexpress NQO1.
Sung YM; Gayam SR; Hsieh PY; Hsu HY; Diau EW; Wu SP
ACS Appl Mater Interfaces; 2015 Nov; 7(46):25961-9. PubMed ID: 26540617
[TBL] [Abstract][Full Text] [Related]
57. Genetic evidence for NAD(P)H:quinone oxidoreductase 1-catalyzed quinone reduction on passage through the mouse pulmonary circulation.
Lindemer BJ; Bongard RD; Hoffmann R; Baumgardt S; Gonzalez FJ; Merker MP
Am J Physiol Lung Cell Mol Physiol; 2011 May; 300(5):L773-80. PubMed ID: 21296895
[TBL] [Abstract][Full Text] [Related]
58. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.
Pey AL; Megarity CF; Timson DJ
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30518535
[TBL] [Abstract][Full Text] [Related]
59. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
Siegel D; Yan C; Ross D
Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors.
Siegel D; Franklin WA; Ross D
Clin Cancer Res; 1998 Sep; 4(9):2065-70. PubMed ID: 9748120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
